ReviewDrug design, development and therapy2025
Traditional Chinese Medicine and Ferroptosis in Intracerebral Hemorrhage: A Potential Therapeutic Approach.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Therapeutic Potential of Traditional Chinese Herbal Medicines in Intracerebral Haemorrhage: A Narrative Review.Neurology and therapy · 2026Review
- Iron, Copper, and Zinc Dyshomeostasis in Cardiovascular and Cerebrovascular Diseases: Redox Mechanisms, Evidence Levels, and Translational Prospects.International journal of molecular sciences · 2026Review
- Pan-Cell Death Protein Signature as a Novel Diagnostic and Prognostic Biomarker for Intracerebral Hemorrhage.Journal of proteome research · 2026Article
- Targeting ferroptosis in osteoporosis: mechanisms and natural products therapies.Frontiers in pharmacology · 2026Review
- Metabolic dysfunction-associated fatty liver disease exacerbates hematoma expansion in intracerebral hemorrhage: an explainable machine learning approach.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracerebral hemorrhage (ICH) is a severe cerebrovascular disorder associated with high morbidity and mortality. Ferroptosis, a regulated form of cell death characterized by iron accumulation and lipid peroxidation, plays a critical role in secondary injury following ICH. Traditional Chinese Medicine (TCM) has demonstrated distinct therapeutic benefits in cerebrovascular disease, and emerging evidence suggests its potential to modulate ferroptosis. This review explores the therapeutic effects of TCM and TCM-based interventions for ICH, with a focus on their regulation of ferroptosis-related mechanisms. In ICH, ferroptosis is driven by disrupted iron metabolism, lipid peroxidation, oxidative stress, and neuroinflammation-key contributors to secondary brain injury. TCM interventions, including herbal medicines, active compounds, and acupuncture, may counteract these processes by restoring iron homeostasis and reducing oxidative stress, thereby improving neurological outcomes. Given the critical role of ferroptosis in ICH pathophysiology, TCM represents a promising avenue for targeting ferroptosis-related pathways and advancing therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.